IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Source Summary

Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026 Updated data from Phase 2...